How RECELL Spray-On Skin Works for Burns and Vitiligo

RECELL is a point-of-care device that turns a small sample of your own skin into a sprayable suspension of living cells, which a surgeon then applies directly onto a wound or depigmented patch. Approved by the FDA for treating burns, and more recently for stable vitiligo, it works by harvesting keratinocytes, melanocytes, and fibroblasts from a thin biopsy and delivering them as a fine mist. The technology sits between a traditional skin graft and a lab-cultured cell sheet, and the clinical picture around it is more nuanced than the word “spray” might suggest.

How the Cell Suspension Is Made

The whole process happens in the operating room, not a remote lab. A surgeon takes a thin split-thickness skin sample, often around four square centimeters, and places it into a warmed enzyme solution for roughly 15 to 20 minutes. That enzyme breaks down the bonds holding cells together and loosens the junction between the outer epidermis and the deeper dermis. Once the two layers separate freely, they are rinsed and placed on a sterile tray. The surgeon then scrapes both the dermal and epidermal surfaces with a scalpel blade to fully disaggregate the tissue into individual cells. Those cells are suspended in a buffer solution, filtered, drawn into a syringe, and sprayed over the wound bed.¹

Because the cells come from you, the suspension contains the same melanocytes responsible for your skin color, the keratinocytes that form the outer barrier, and the fibroblasts that support the structural matrix underneath. That mix is what separates RECELL from a pure keratinocyte spray or a cultured graft that may lack pigment-producing cells entirely. The preparation adds under 30 minutes to surgery time in practice, since the enzyme incubation runs in parallel with wound debridement.²

What It Does for Burn Patients

The original and still primary use of RECELL is in acute burn care, where the central problem is that traditional split-thickness skin grafts demand a large donor site. The bigger the burn, the less unburned skin remains to harvest. In a pivotal trial, burn sites treated with RECELL needed roughly 97.5 percent less donor skin than those treated with a standard meshed autograft. Patients who received the cell spray reported significantly less donor-site pain, greater satisfaction with donor-site appearance, and better scar outcomes at the harvest location.³

A randomized trial of 82 patients comparing RECELL with classic skin grafting found that both achieved adequate wound coverage, but the spray required a much smaller biopsy area and caused less postoperative pain. The trade-off was speed: conventional grafting achieved wound closure faster in that study. Aesthetic and functional outcomes at follow-up were similar between the two approaches.⁴

Where RECELL really earns its place is in reducing the total amount of donor skin needed when grafting is still part of the plan. In a controlled study of mixed-depth burns, mean donor skin use dropped by about 32 percent when RECELL was added alongside meshed autografts, a statistically significant reduction.⁵ Practically, this means surgeons can use wider mesh ratios on whatever graft they do take, stretching a smaller piece of skin over a larger wound, while the sprayed cells fill in the gaps.

Beyond Burns: Treating Vitiligo

Vitiligo, the autoimmune condition that destroys melanocytes and leaves pale patches of skin, has become the second major frontier for RECELL. Because the spray suspension includes melanocytes alongside keratinocytes, it can repopulate pigment-producing cells in areas where the immune system has wiped them out, provided the disease is stable and no longer actively destroying pigment.

A randomized controlled trial in 25 subjects found that 36 percent of spray-treated vitiligo lesions achieved at least 80 percent repigmentation by week 24, compared with zero percent for control lesions. The repigmentation held up through week 52, suggesting it was durable and not just a temporary effect.⁶ A larger study in a diverse patient population showed even more encouraging numbers: by week 24, about two-thirds of lesions had more than 50 percent repigmentation, and roughly 42 percent reached at least 80 percent.⁷

The emphasis on “stable” vitiligo matters. If the disease is still actively progressing, spraying new melanocytes into the affected area is likely to end in the immune system destroying them again. Stability, usually defined as no new patches and no expansion of existing patches for at least a year, is a prerequisite for candidacy. The procedure also requires light dermabrasion of the recipient site before spraying, which creates a controlled superficial wound for the cells to attach to. That adds some post-procedure healing time and temporary redness, but the donor biopsy itself is tiny compared to older surgical approaches for vitiligo like suction-blister grafting.

Where Spray-on Cells Fall Short

The technology does not work equally well for every wound type. A randomized trial in patients with large diabetic foot ulcers found no evidence that spray-on skin offered any benefit over standard wound care in terms of six- or twelve-month cure rates, healing trajectory, or quality of life.⁸ Diabetic foot wounds are a fundamentally different biological problem from burns: they involve impaired blood supply, chronic inflammation, neuropathy, and often ongoing mechanical pressure. Spraying healthy cells onto a wound bed with poor vasculature does not solve the underlying reasons the wound refuses to heal.

The picture for venous leg ulcers is somewhat more promising. A multi-center randomized trial showed that RECELL combined with compression therapy produced a significantly greater reduction in ulcer area at 14 weeks compared to compression alone, with the benefit most pronounced in larger ulcers. Patients in the spray group also reported less pain and improved quality of life.⁹ But this was still a pilot trial with a small sample size, and the finding that the effect was concentrated in large ulcers means it may not generalize to all venous ulcer patients. The difference between diabetic foot wounds and venous ulcers tracks with what you would expect: venous ulcers generally have better blood supply once compression is restored, giving sprayed cells a healthier wound bed to work with.

Use in Children and Trauma

Pediatric burn care presents its own challenges because children have less total body surface area to harvest donor skin from, and scarring during growth years can lead to contractures that limit movement. A case series evaluating RECELL in pediatric burn patients found the device safe and effective, providing an additional tool for wound coverage either alone or alongside traditional grafting.¹⁰ Five patients in that series who received skin grafts did experience graft loss, and three of those had graft loss in areas where RECELL was applied, a reminder that the spray is not immune to the same healing failures that can affect conventional grafts.

RECELL has also been studied in traumatic wounds beyond burns, including degloving injuries, soft tissue defects from infection, and surgical wound complications. A randomized controlled trial in patients with full-thickness skin defects found that the most common indications were post-infection surgical wounds and degloving injuries.¹¹ The logic for using spray cells in trauma mirrors the burn rationale: when you have large defects and limited donor sites, anything that stretches the available skin further has value.

How It Compares to Cultured Skin Grafts

Before RECELL, the main alternative for patients who needed more wound coverage than their donor sites could provide was cultured epidermal autografts, commercially known as Epicel. That process involves taking a small full-thickness skin biopsy, shipping it to a laboratory, and growing keratinocyte sheets in culture over a period of 16 to 21 days before the graft is ready to apply.¹² That waiting period is the fundamental drawback: a critically burned patient cannot always wait two to three weeks for wound coverage.

RECELL’s point-of-care preparation eliminates the lab wait entirely. A cost-effectiveness analysis modeled the two approaches against each other in massive burns and found that spray keratinocytes achieved successful wound closure in 88 percent of simulations versus 73 percent for cultured autografts, while also saving an estimated $254,743 per patient with no compromise in scar quality.¹³ The cultured graft approach also produces pure keratinocyte sheets that lack melanocytes and fibroblasts, meaning the resulting skin may not match the patient’s pigmentation and may lack some structural support that a mixed-cell suspension provides.

The Cost Question

A single RECELL kit is not cheap, and hospital procurement teams understandably want to know whether the device justifies its price. The available economic analyses are encouraging. A modeling study found that using RECELL is cost-saving or essentially cost-neutral across expected patient profiles, with burn centers saving roughly 14 to 17 percent annually. The savings come primarily from shorter hospital stays and fewer return trips to the operating room.¹⁴

An analysis of real-world data from U.S. burn centers put more specific numbers on this. Patients treated with the spray suspension, with or without a conventional graft, had an average hospital stay about two days shorter than those treated with grafts alone, translating into overall cost savings of roughly $22,000 per patient.¹⁵ For large burns especially, those savings add up quickly, since each additional day in a burn unit is extraordinarily expensive. One practical way to further reduce per-patient costs is reusing the enzyme solution: a study showed that a single enzyme vial could be used for at least seven successive biopsies without any decrease in cell yield or clinical outcome.¹⁶

Practical Handling and Cell Viability

Once the cell suspension is prepared, timing matters but is not as tight as you might expect. Characterization studies show that total viable cell count remains stable for at least four hours at room temperature and for up to 24 hours when stored at refrigerator temperature.¹⁷ That flexibility is important in a busy operating room where the timing between preparation and application may not be perfectly synchronized.

The spray step itself introduces its own variables. When living cells are aerosolized and hit a wound surface, some inevitably get damaged by the impact. Cell survival after spraying depends on a range of physical factors: higher air pressure, smaller nozzle diameter, faster droplet velocity, and a stiffer receiving tissue surface all reduce viability. On the other hand, larger droplet size and lower-viscosity carrier fluid help protect cells during delivery.¹⁸ Surgeons learn to optimize spray distance and pressure with experience, but this is one area where technique can meaningfully influence outcomes. It’s not simply “point and spray.”

Combining Spray Cells with Dermal Templates

For deep, full-thickness wounds where the dermis has been completely destroyed, spraying cells alone is not enough. You need something for those cells to live on and grow into. A pilot study explored combining RECELL with a dermal regeneration template, a synthetic scaffold that mimics the structure of the lost dermis, followed by autografting. The combination reduced the amount of donor skin needed and improved repigmentation compared with dermal template and autograft alone.¹⁹ The logic is straightforward: the template provides the structural scaffold, the graft provides bulk coverage, and the sprayed cells fill in the interstices with a broader mix of cell types than the graft alone would deliver.

This multi-layered approach is still evolving and is primarily used in specialized burn centers with experience managing all three components. It illustrates a broader point about RECELL: the device is rarely a standalone replacement for grafting in severe injuries. It is most often an adjunct that lets surgeons do more with less donor skin, not a way to skip harvesting altogether.

What Patients Actually Experience

From the patient’s perspective, the practical differences center on the donor site. A traditional skin graft requires harvesting a sheet of skin that leaves a raw wound roughly the size of the burn being covered. That donor wound can be intensely painful, sometimes more so than the burn itself, and it generates its own scar. With RECELL, the biopsy needed is tiny, typically a postage-stamp-sized piece. Patients in the pivotal burn trial reported significantly less donor-site pain and significantly higher satisfaction with how their donor site looked afterward.²⁰

Recovery expectations vary depending on what the spray was used for. In burn care, the treated area typically goes through the same wound-maturation process as any graft, with redness gradually fading over months. In vitiligo, patients begin to see pigment returning within a few weeks, but full color matching can take several months and may never reach 100 percent. Setting realistic expectations is important, especially for vitiligo patients who sometimes hear “spray-on skin” and imagine an instant cosmetic fix.

Ongoing Research and Emerging Directions

The concept of spraying living cells onto damaged tissue has attracted interest well beyond human burn units. In veterinary medicine, researchers have explored spray-on skin techniques for equine wound healing, particularly on the distal limbs of horses where wounds heal slowly and produce exuberant granulation tissue. A scoping review of the equine wound literature found that while case reports and case series consistently reported positive outcomes, only about 36 percent of experimental studies showed significant healing improvement compared to control groups, a sobering reminder that observational enthusiasm does not always survive controlled testing.²¹

In human medicine, next-generation spray systems are exploring whether adding bioactive carriers, growth factors, or pre-seeded scaffolds to the cell suspension could improve cell survival and speed healing further. The core challenge remains the same one that has defined the technology from the start: how to keep fragile living cells alive through the spray process and provide them with a wound environment where they can proliferate, differentiate, and ultimately become functional skin. The RECELL device solved the logistics of cell preparation at the bedside. The biology of what happens after those cells land on the wound is still being optimized.